Skip to content
Text “Loti” to 833-962-6682 to join the Loti Labs VIP Group!
Loti Labs Resources Peptides

Next-Generation Triple Hormone Receptor Agonists: GLP-1R/GIPR/GCGR Peptide Design Research

How computational design balances GLP-1R, GIPR, and GCGR potency ratios in next-gen triple agonist candidates like ASC37.

Two-receptor incretin agonists changed the trajectory of metabolic peptide design almost overnight. Now the field has already moved to the next frontier: triple receptor agonists that engage GLP-1R, GIPR, and GCGR simultaneously within a single peptide backbone. Building a molecule that can hit three distinct class B GPCRs with balanced, tunable potency is a genuinely hard computational and medicinal chemistry problem, and it’s reshaping how researchers think about metabolic peptide architecture.

This article walks through the computational design strategies behind next-generation triple hormone receptor agonists, half-life engineering in candidates such as ASC37, and the persistent challenge of balancing potency ratios across three receptor targets at once.

The Case for a Third Receptor

GLP-1R, GIPR, and GCGR are class B GPCRs with overlapping but distinct ligand recognition profiles. A triple agonist combines activity at these receptors in one peptide. The design question is how sequence changes affect binding and downstream signaling at each receptor, and how to compare those changes across assay systems.

Computational Design for Metabolic Stability

Native GLP-1, GIP, and glucagon peptides share structural homology but differ enough in sequence that engineering a single backbone to activate all three receptors requires careful residue-by-residue optimization. Computational approaches now commonly used include molecular dynamics simulation of receptor-ligand complexes, machine learning-guided sequence optimization trained on binding affinity datasets, and rational substitution at positions known to affect protease resistance.

Protecting Against Enzymatic Degradation

Native GLP-1 and GIP are susceptible to cleavage by dipeptidyl peptidase-4 (DPP-4). Replacing the alanine at position 2 with a non-natural amino acid such as aminoisobutyric acid (Aib) is a common design strategy for reducing that cleavage. Fatty acid or fatty diacid conjugation can add albumin binding, another molecular feature associated with longer circulating half-life.

Lipidation and Elimination Half-Life

ASC37 and related candidates illustrate the interest in extended elimination half-life. Lipidation and other structural changes are evaluated for their effects on albumin binding, clearance, and receptor-mediated internalization. Comparing pharmacokinetic results requires attention to the experimental model, sampling period, and analytical method, rather than treating values from different study designs as interchangeable.

A longer elimination half-life does not, by itself, describe the full concentration-time curve. Comparing peak concentrations, overall exposure, and the rate of decline gives a more complete picture of pharmacokinetic behavior in a specified experimental model.

Balancing Three-Receptor Potency Ratios

Perhaps the hardest part of triple agonist design is not simply activating all three receptors, but choosing their relative activities. A sequence change can shift potency at one receptor more than at another. Comparing concentration-response curves in matched assays helps distinguish those shifts from differences caused by receptor expression or assay conditions.

  • GLP-1R-dominant designs show greater relative activity at GLP-1R in a specified assay system
  • GLP-1R/GCGR balance is assessed by comparing concentration-response curves at the two receptors
  • GIPR contribution is generally the hardest to isolate functionally in in-vivo research models

Reported EC50 values across in vitro reporter assays for early triple-agonist candidates and newer molecules show single-digit to double-digit picomolar potency at GLP-1R, with somewhat higher (less potent) EC50 values typically reported at GCGR, reflecting deliberate design choices rather than incidental imbalance.

Species Translation and Model Considerations

A recurring complication in this research area: rodent and non-human primate receptor sequences don’t always predict human receptor pharmacology precisely, particularly for GCGR, where species-specific differences in extracellular loop structure can shift binding behavior. In diet-induced obese mouse studies, researchers measured body weight-related endpoints. Comparisons of receptor potency across species require in vitro characterization of the corresponding receptor variants under matched assay conditions.

Research Outlook

Triple hormone receptor agonist design sits right at the intersection of structural biology, computational chemistry, and metabolic physiology, and the pace of new candidate disclosures hasn’t slowed. Expect continued refinement of lipidation chemistry, more sophisticated machine learning models trained on expanding binding datasets, and deeper mechanistic work clarifying exactly how GIPR contributes to the overall metabolic effect profile. Whether four-receptor designs are next remains genuinely uncertain, but the trajectory of this field suggests investigators aren’t done adding complexity in pursuit of better balanced pharmacology.

Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.

Research-use notice

This educational material discusses laboratory research concepts only. Loti Labs products are intended strictly for research and development use and are not for human consumption.

Ready to explore?

Browse high-purity research materials by format or view the full catalog.